IRWD

Rating neutralAI Memo

Ironwood

As of 2026-05-27/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Apraglutide STARS-2 trial initiation window opens in Q2 2026 • 2026-06-30

Expected move: +60%

Biggest risk

The bear case is that IRWD remains too dependent on LINZESS economics, so any disappointment in the pediatric decision, gross-to-net phasing, or STARS-2 execution would quickly pressure the multiple. CFO turnover and any guidance wobble would reinforce the discount rather than justify a premium.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The bull case is that LINZESS continues to compound, the pediatric FC label expansion lands, and apraglutide advances into STARS-2 initiation, giving the stock a second rerating lane beyond the core cash engine. If the cash flow trajectory stays strong, the market can look through the CFO transition and keep rewarding the franchise.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-27

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 update reaffirmed the LINZESS cash engine
CFO transition adds governance noise but is not a thesis driver
May 24 pediatric LINZESS PDUFA is the cleanest near-term rerating event

BearKey bullets

Apraglutide remains execution-sensitive; confirmatory STARS-2 timing, design, and site-start progress are still early and could slip.
LINZESS concentration remains the core risk, especially if prescription demand or net price normalizes after a strong quarter.
The CFO transition introduces governance and execution noise in the near term, even if the company says the resignation was not related to reporting disagreements.

WatchKey bullets

Apraglutide STARS-2 trial initiation window opens in Q2 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $6 (p=45%)

Bull/Bear spread: +143% / -35%

Vs latest close: Bull +143% · Base +60% · Bear -35%

Scenario probabilities

Bull Target: $9 (p=25%)Base Target: $6 (p=45%)Bear Target: $2 (p=30%)

Commentary

Primary-source flow is modestly constructive, but this remains a monitoring-style memo rather than a high-conviction re-rating call. The packet has no fresh analyst revision cluster and no independently quantified post-print market reaction, so the Q1 strength, pediatric PDUFA, and apraglutide timeline should be treated as the main evidence with low-coverage caution.

As of 2026-05-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 update reaffirmed the LINZESS cash engine
CFO transition adds governance noise but is not a thesis driver
May 24 pediatric LINZESS PDUFA is the cleanest near-term rerating event

Scenarios

Bull Target (Scenario probability)

$9 / p=25% prob

Base Target (Scenario probability)

$6 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Price $4 as of 2026-05-28

Nearest Scenario: Bear (∆ 35%)

Targets vs latest close: Bull +143% · Base +60% · Bear -35%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
Apraglutide STARS-2 trial initiation window opens in Q2 2026
The 10-Q says Ironwood and FDA aligned on key STARS-2 Phase 3 design elements and expects site initiations to begin in Q2 2026, keeping apraglutide as the main long-duration pipeline option and the clearest non-LINZESS rerating lever. [#10-Q-2026-05-07]
Prob 70.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q1 2026 update reaffirmed the LINZESS cash engine
2026-05-07
Ironwood’s first-quarter release showed LINZESS U.S. net sales up 97% year over year to $272.5 million, prescription demand up 5%, and management maintained full-year 2026 financial guidance; that supports near-term cash generation but also keeps the equity concentrated in one commercial asset. [#IR-2026-05-07]
Prob 90% • Move 8% • Priced-in 75%
CFO transition adds governance noise but is not a thesis driver
2026-05-15
The 8-K disclosed CFO Gregory Martini’s resignation effective May 15, 2026, with Ronald Silver stepping in as interim CFO; that does not change the operating thesis by itself, but it adds near-term management-transition risk. [#8-K-2026-05-13]
Prob 50% • Move 2% • Priced-in 70%
May 24 pediatric LINZESS PDUFA is the cleanest near-term rerating event
2026-05-24
The company disclosed FDA priority review for the sNDA in functional constipation for children ages 2 to 5 and set a May 24, 2026 PDUFA date; approval would broaden the label, while a delay or rejection would keep the stock anchored to a single franchise. [#IR-2026-05-07]
Prob 60% • Move 11% • Priced-in 45%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Apraglutide remains execution-sensitive; confirmatory STARS-2 timing, design, and site-start progress are still early and could slip.
LINZESS concentration remains the core risk, especially if prescription demand or net price normalizes after a strong quarter.
The CFO transition introduces governance and execution noise in the near term, even if the company says the resignation was not related to reporting disagreements.
The May 24 pediatric LINZESS PDUFA can still disappoint, delay, or create a sell-the-news reaction even after positive momentum into the date.

Peers

Symbol	Summary
CRMD	Closest of the candidate peers for a narrow commercial biotech frame: useful for thinking about how concentrated product economics, execution discipline, and balance-sheet management affect valuation.
CLYM	A smaller, more event-driven biotech comp where catalyst timing and volatility matter more than stable commercial cash flow; useful for framing binary-event sensitivity rather than direct operating comparability.
ACRS	Another small-cap biotech comp that is more helpful for valuation and volatility context than for direct franchise comparison because its operating mix is much less commercial than IRWD’s.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-27

AI Stock Memo: IRWD - Ironwood - RankAlpha